Contact:
4008465777
Tonghua Dongbao selected as one of top 100 most valuable Mainboard-listed companies
Date：2021-10-20
Author：Dongbao
Views：9
On September 28, Securities Times and Caitong Securities published the Ranking of Listed Companies in China by Value for 2021. Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) was ranked among the top 100 most valuable Mainboard-listed companies.
The final ranking was determined by more than 20 experts from regulators, academia, brokers, and funds after a thorough review of the candidates in accordance with a strict, standard procedure. Companies in the ranking all boast: a dominant position in the industry, an excellent management team, a solid reputation in the capital market, great brand awareness in the consumer market, financial sustainability, ability to provide a compelling return to investors, a sound and standardized information disclosure system, and active CSR engagement. Tonghua Dongbao’s inclusion in the ranking fully demonstrates the recognition by the society and capital market of the Company’s comprehensive strength. The top 100 most valuable Mainboard-listed companies will make up the CSI Securities Times Main Board Value 100 Index. The constituent changes will be made in six trading days.
As a leading insulin manufacturer in China, Tonghua Dongbao has been dedicated to developing diabetes drugs for years. Tonghua Dongbao has rolled out various generations and types of insulin and sought continuous expansion in the field of endocrinology. It has also kept enriching the R&D portfolios to exploit the field of novel drugs. In H1 2021, the Company recorded operating revenue of RMB 1.662 billion, up 12.71% YoY, and a net profit attributable to owners of the parent company of RMB 674 million, up 24.47% YoY. The overall revenue from insulin products hit RMB 1.439 billion, an increase of 15.19% YoY.
Tonghua Dongbao continues to optimize its corporate governance, management system, and incentive mechanism, aiming to further enhance the overall operations and efficiency of the Company. In Q1 2021, the Company bought back nearly RMB 120 million worth of shares for employee equity incentives, which demonstrates the management's recognition of the Company's value, and the Company's willingness to launch continued employee equity incentives and establish a long-term mechanism for the common growth of employees and the Company. In July, the Board of Directors of the Company approved a plan to buy back shares worth up to RMB 360 million and cancel them to return surplus cash to shareholders. This move further demonstrates the management’s recognition of the Company’s strategic transformation, confidence in the Company's future development, and determination to strengthen the return to shareholders and safeguard their interests.
Tonghua Dongbao will keep improving its governance structure, incentive mechanism, and product portfolios. While consolidating and expanding its competitive advantages in insulin products, the Company, guided by the philosophy of "Establishing a Global Brand Through Consistent Innovation", will continue to focus on the R&D of cutting-edge and key technology for treating diabetes and other endocrine diseases and promote innovation to achieve its vision of being an explorer and leader of novel drugs R&D in the field of endocrinology as soon as possible.
